Funding

This study was supported by Celltrion Healthcare France S.A.S.

Conflicts of interest

G. Bouguen reports conflicts of interest from AbbVie, Amgen, Biogen, Celltrion Healthcare, Fresenius Kabi, Galapagos, Gilead, Janssen, Lilly, Pfizer, Sandoz, and Takeda. L.G. reports conflicts of interest from AbbVie, Amgen, Biogen, BMS, Celltrion Healthcare, Galapagos, Janssen, Lilly, MSD, Novartis, Pfizer, Stada, and UCB. V.A. reports conflicts of interest from AbbVie, Amgen, Celltrion Healthcare, Ferring Fresenius, Galapagos, Janssen, Lilly, Nordic, Pfizer, Sandoz, Takeda, Tillotts, and Viatris. E.S. reports conflicts of interest from AbbVie, Fresenius, IQVIA Nordics, Celltrion Healthcare, Lilly, Nordic, Sandoz, and UCB. G. Bonnaud reports conflicts of interest from AbbVie, Alfasigma, Bouchara-Recordati, Celltrion Healthcare, Ferring, Janssen, Galapagos, Gilead, Medtronic, MSD, Norgine, Pfizer, Roche, Sandoz, Takeda, Tillotts, and Viatris. X.R. reports conflicts of interest from AbbVie, Amgen, Celltrion Healthcare, Ferring, Janssen, Lilly, Pfizer, Takeda, and Theradiag. Y.B. reports conflicts of interest from AbbVie, Alimentiv, Amgen, Biogaran, Biogen, Boehringer Ingelheim, Celltrion Healthcare, Eli Lilly, Ferring, Fresenius Kabi, Galapagos, Gilead, Hospira, Iterative Health, Janssen, Lilly, Mayoli Spindler, Merck, MSD, Norgine, Pfizer, Roche, Sandoz, Sanofi, Shire, Takeda, Tillotts, UCB, and Viatris. S. Nancey reports conflicts of interest from AbbVie, Amgen, Biogen, Celltrion Healthcare, Fresenius Kabi, Galapagos, Janssen, Lilly, Pfizer, Sandoz, and Takeda. N.M. reports conflicts of interest from Celltrion Healthcare. J.F. reports conflicts of interest from AbbVie, Amgen, Biogen, Celltrion Healthcare, Ferring, HAC Pharma, Janssen, MSD, Pfizer, Sandoz, and Takeda. L.V. reports conflicts of interest from AbbVie, Amgen, Celltrion Healthcare, Ferring, Galapagos, Janssen, Lilly, MSD, Pfizer, Takeda, and Viatris. S. Nahon reports conflicts of interest from AbbVie, Amgen, Biogen, Celltrion Healthcare, Ferring, Galapagos Janssen, MSD, Takeda, and Tillotts. A. Dellal reports conflicts of interest from AbbVie, Celltrion Healthcare, and Fresenius Kabi. A. Denis, L.F., C.H., and S.B. are employees of Celltrion Healthcare France. H.M. reports conflicts of interest from AbbVie, Biogen, BMS, Celltrion Healthcare, Fresenius Kabi, Galapagos, Janssen, Lilly, MSD, Nordic Pharma, Novartis, Pfizer, Roche Chugai, and Sanofi.

Availability of data and material

The datasets supporting the conclusions of this article are available from the corresponding author upon reasonable request.

Ethics approval

The study protocol was approved on June 2, 2022, by the independent Ethics Committee of “Nord Ouest 3” France (reference number: 2022-A00448-35), which covers all participating centers. The study was conducted in accordance with the ethical principles of the Declaration of Helsinki and all applicable local regulations.

Consent to participate

All patients in this study provided written informed consent to participate.

Consent for publication

Not applicable.

Code availability

Not applicable.

Author contributions

G. Bouguen, H.M., L.G., V.A., E.S., G. Bonnaud, A. Denis, L.F., C.H., and S.B. contributed to the study design and methodology. G. Bouguen, E.S., G. Bonnaud, X.R., Y.B., S. Nancey, N.M., J.F., L.V., S. Nahon, A. Dellal, and H.M. collected study data. All authors reviewed and critically revised the manuscript, provided final approval of the version to be published, and agree to be accountable for its accuracy and integrity.